The $200,000 revenue was primarily from the trial with the US Pharrma company, no actual VX patient revenue, however they have said this will be in the March Quarter but as I have noted they have shown any tendency to update us and my assumption is this will be very slow going for now.
- Forums
- ASX - By Stock
- Ann: 4DMedical Reports 1H FY22 Results
The $200,000 revenue was primarily from the trial with the US...
Featured News
Add 4DX (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.5M |
Open | High | Low | Value | Volume |
42.5¢ | 43.0¢ | 41.5¢ | $46.59K | 111.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 87061 | 42.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 9979 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.425 |
1 | 87061 | 0.420 |
3 | 16555 | 0.415 |
8 | 133354 | 0.410 |
3 | 63000 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 9999 | 2 |
0.440 | 278 | 1 |
0.445 | 87348 | 3 |
0.450 | 1000 | 1 |
0.455 | 10000 | 1 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
4DX (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online